Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-31
2009-11-24
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S258100
Reexamination Certificate
active
07622470
ABSTRACT:
T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m2. In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m2per dose.
REFERENCES:
patent: 4393064 (1983-07-01), Degraw et al.
patent: 4433147 (1984-02-01), Degraw et al.
patent: 4652533 (1987-03-01), Jolley
patent: 4843155 (1989-06-01), Chomczynski
patent: 5354751 (1994-10-01), DeGraw et al.
patent: 5981592 (1999-11-01), Wechter et al.
patent: 6028071 (2000-02-01), Sirotnak et al.
patent: 6323205 (2001-11-01), Sirotnak et al.
patent: 6410696 (2002-06-01), Davalian et al.
patent: WO 98/02163 (1998-01-01), None
patent: 2005/117891 (2005-12-01), None
patent: 2005/117892 (2005-12-01), None
Matsuo et al., “Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma”, Blood, vol. 97, No. 10, pp. 3205-3209 (2001).
Gerald D. Weinstein, “Diagnosis and Treatment: Drugs Five Years Later: Methotrexate”, Annals of Internal Medicine, vol. 86, pp. 199-204 (1977).
Grenzebach et al. Annals of Hematology, 2001, vol. 80, Suppl. 3, pp. B73-B76 (Abstract attached).
Liang et al. Hematological Oncology, 1992, vol. 10, pp. 155-161 (Abstract attached).
Fouchard et al: Leukemia, 1998, vol. 12, pp. 578-585 (Abstract attached).
Au et al. British Journal of Dermatology, 2000, vol. 143, pp. 408-410.
Starling et al, Drug trials in neuroblastoma: cyclophosphamide (NSC-26271) Alone; Vincristine (NSC-67574) plus cyclophosphamide; 6-mercaptopurine (NSC-755) plus 6-methylmercaptopurine riboside (NSC-40774); and cytosine arabinoside (NSC-63878) alone, Cancer Chemotherapy Reports, vol. 58, No. 5, p. 683-687, Sep./Oct. 1974.
DeGraw et al, Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin, Journal of Medicinal Chemistry, 1993.
Wang et al, Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor rfc-1 gene expression, Leukemia & Lymphoma, vol. 44, p. 1027-1035, 2003.
Krug et al, 10-propargy1-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer, Clinical Cancer Research, vol. 9, p. 2072-2078, Jun. 2003.
Awar, Omar et al. “Treatment of Transformed Mycosis Fungoides with Intermittent Low-Dose Gemcitabine.” Oncology Sep. 23, 2007, pp. 103-135, vol. 73, Department of Internal Medicine.
Bekkenk, Marcel et al. “Peripheral T-Cell Lymphomas Unspecified Presenting in the Skin: Analysis of Prognostic Factors in a Group 82 Patients.” Blood Sep. 13, 2003, pp. 2213-2219, vol. 102, No. 6, The American Society of Hematology.
Cheson, Bruce et al. “Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma's.” 1999, pp. 1244-1253, vol. 117, No. 4, Journal of Clinical Oncology.
Howard, Michael et al. “Mycosis Fungoides: Classic Disease and Variant Presentations.” 2000, pp. 91-99, vol. 19, No. 2, Departments of Pathology and Dermatology.
Mercadal, S. et al. “Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stemOcell transplantation in previously untreated patients with peripheral T-cell lymphoma.” Annals of Oncology 2008, pp. 958-963, vol. 19, Oxford University.
www.nccn.org “Non-Hodgkins's Lymphomas” V.3.2008, Apr. 10, 2008, National Comprehensive Cancer Network.
Olsen, Elise et al. “Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Orginization of Research and Treatment of Cancer (EORTC).” Blood, Sep. 15, 2007, pp. 1713-1722, vol. 110, No. 6, The American Society if Hematology.
Prochazkova, Martina et al. “Large Cell Transformation of mycosis fungoides: tetraploidization within skin tumor large cells.” Cancer Genetics and Cytogenetics 2005, pp. 1-6, vol. 163.
Quereux, Gaelle et al. “Prospective Multicancer Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sezary Syndrome.” Arch Dermatology 2008, pp. 727-733, vol. 144, No. 6.
Rodriguez-Abreu, Delvys et al. “Peripheral T-cell Lymphomas, unspecified (or not otherwise specified): a review.” Hematol Oncol. 2008 pp. 8-20, vol. 26.
Rosen, Steven et al. “Primary Cutaneous T-Cell Lymphomas.” 2006, pp. 323-330, American Society of Hematology.
Savage, K. et al. “Characterization of peropheral T-cell lymphomas in a single North American institution by the WHO classification.” Annals of Oncology2004 pp. 1467-1475, vol. 15.
Vergier, Beatrice et al. “Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases.” Blood, Apr. 1, 2000, pp. 2212-2218, vol. 95, No. 6.
Vonderheid, Eric et al. “Treatment Planning in cutaneous T-Cell Lymphoma.” Dermatologic Therapy 2003, pp. 276-282, vol. 16.
Wang, Eunice et al. “Activity of a Novel Anti-folate (PDX, 10-propargyl-10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression.” Leukemia and Lymphoma 2003, pp. 1027-1035, vol. 44, No. 6.
Weidmann, E et al. “Diagnosis and actual therapy strategies in peripheral T-Cell lymphomas: summary of an international meeting.” Annals of Oncology 2004, pp. 369-374, vol. 15.
Molina, Julian et al. “Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.” IDrugs, 2008, pp. 508-521, vol. 11, No. 7, Drug Profile.
“Methotrexate Injection, USP.” Mayne, 2005, pp. 1-26.
Nair, M. et al. “Synthesis and Biological Evaluation of Poly-y-glutamyl Metabolites of 10-Deazaaminopterin and 10-Ethyl-10-deazaaminopterin.” J. Med Chem. 1988, pp. 181-185, American Chemical Society.
O'Connor, Owen. “Developing new drugs for the Treatment of lymphoma.” European Journal of Haematology, 2005, pp. 150-158, vol. 75 (Supp 66), Blackwell Munksgaard.
O'Connor, Owen et al. “A Phase ‘2-1-2’ Study of Two Different Doses and Schedules of Pralatrexate, A High Affinity Substrate for the Reduced Folate Carrier (rfc-1), in Patients with Relapsed or Refactory Lymphoma Reveals Marked Activity in T-Cell Malignancies.” AACR, 2007.
O'Connor, Owen et al. “Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.” Blood, 2006, pp. 1-2, vol. 108, American Society of Hematology, Abstract 400.
O'Connor, Owen et al. “Pralatrexate (10-propargyl-10-deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity.” Blood, 2005, pp. 1-2, vol. 106, American Society of Hematology, Abstract 2678.
O'Connor, Owen et al. “Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier type 1, produces marked complete and durable remissions in a diversity of chemotherapy refactory cases of T-cell lymphoma.” Journal Compilation, 2007, pp. 425-428, vol. 139, Black well Publishing Ltd.
O'Connor, Owen. “Pralatrexate: an emerging new agent with activity in T-cell lymphomas.” Current Opinion in Oncology, 2006, pp. 591-597, vol. 18, Lippincott Williams & Wilkins.
O'Connor, Owen et al. “Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.”
O'Connor Owen A.
Sirotnak Francis M.
Anderson James D
Larson & Anderson LLC
Marschel Ardin
Sloan-Kettering Institute for Cancer Research
LandOfFree
Treatment of T-cell lymphoma using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of T-cell lymphoma using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of T-cell lymphoma using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4119645